

6. An expression vector comprising a polynucleotide comprising a nucleic acid sequence encoding the affinity binding entity of any one of claims 1-5 operably linked to a cis-acting regulatory element.

7. A cell comprising the expression vector of claim 6.

8. An *in vitro* method of detecting a cancer cell, comprising contacting the cell with the antibody of any one of claims 3-5, under conditions which allow immunocomplex formation, wherein a presence of said immunocomplex or level thereof is indicative of the cancer cell.

9. An *ex vivo* method of diagnosing cancer in a subject in need thereof, comprising contacting a cell of the subject with the antibody of any one of claims 3-5, under conditions which allow immunocomplex formation, wherein a presence of said immunocomplex or level thereof is indicative of the cancer.

10. Use of the affinity binding entity of any one of claims 1-5, the vector of claim 6 or the cell of claim 7 in the manufacture of a medicament for treating a cancer comprising tumor cells that express an antigen specifically recognized by the affinity binding entity.

11. The use of claim 10, wherein said cancer is selected from the group consisting of melanoma and glioblastoma.